Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 322,375 shares of the company’s stock after selling 6,873 shares during the quarter. Bank of New York Mellon Corp owned about 0.22% of Xeris Biopharma worth $1,093,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of XERS. R Squared Ltd acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $42,000. Quantbot Technologies LP purchased a new stake in Xeris Biopharma in the third quarter valued at approximately $44,000. Sunpointe LLC acquired a new position in Xeris Biopharma during the fourth quarter worth $71,000. Janney Montgomery Scott LLC boosted its position in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after buying an additional 5,500 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Xeris Biopharma by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after buying an additional 2,954 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

XERS has been the topic of several research reports. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Leerink Partners increased their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average target price of $5.92.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.56% of the company’s stock.

Xeris Biopharma Stock Performance

XERS stock opened at $5.87 on Tuesday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $5.97. The company’s 50 day moving average price is $3.93 and its 200 day moving average price is $3.44. The firm has a market capitalization of $903.63 million, a price-to-earnings ratio of -13.04 and a beta of 2.32.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.